<DOC>
	<DOCNO>NCT01422889</DOCNO>
	<brief_summary>The purpose study compile real-world clinical outcome data ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System routine clinical practice .</brief_summary>
	<brief_title>ION US Post-Approval Study</brief_title>
	<detailed_description>The ION™ stent third-generation Boston Scientific ( BSC ) paclitaxel-eluting coronary stent . It design improved performance specific deliverability radio-opacity maintain similar drug release profile TAXUS Express TAXUS Liberté stent . Following PMA approval FDA ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System ION US Post-Approval study compile real-world clinical outcome data ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System routine clinical practice . Post-approval study drug-eluting stent ( DES ) provide opportunity observe assess patient outcome technology performance real-world setting .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Consented subject receive one ION ( TM ) Coronary Stents Subjects clinically indicate receive ION ( TM ) Coronary Stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>